Treating an atypical protein kinase C enzyme abnormality
Provided herein are compounds, compositions, pharmaceutical formulations, methods of treating and methods of using aPKC inhibitors for treating and/or preventing of aPKC abnormalities.
1. A method of treating insulin resistance in a subject in need thereof comprising:
administering an effective amount of 2-acetylcyclopentane-1,3-dione (ACPD) to the subject in need thereof, wherein the subject in need thereof has insulin resistance.
2. The method of claim 1 , wherein the effective amount ranges from about 0.001 mg to about 1,000 mg.
3. The method of claim 1 , wherein the effective amount is administered in a dosage form formulated for oral, vaginal, intravenous, transdermal, subcutaneous, intraperitoneal, or intramuscular administration.
4. The method of claim 1 , wherein the effective amount ranges from about 0.001 mg to about 100 mg.